EX-10.20 16 a2219122zex-10_20.htm EX-10.20 [*] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities...And Commercialization Agreement • May 5th, 2020 • New York
This Development, Manufacturing and Commercialization Agreement (the “Agreement”) is entered into as of May 5, 2004 (the “Effective Date”) between Corium International, Inc., a Delaware corporation having its principal place of business at 2686 Middlefield Road, Redwood City, CA 94063 and its manufacturing operations at 4558 50th Street, S.E., Grand Rapids, MI 49512, including its Affiliates (“Corium”), and Barr Laboratories, Inc., a Delaware corporation, having its principal place of business at 2 Quaker Road, Pomona, New York 10970-0519, including its Affiliates (including but not limited to Duramed Pharmaceuticals, Inc.) (“Barr”).
EX-10.21 17 a2219122zex-10_21.htm EX-10.21 [*] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities...And Commercialization Agreement • May 5th, 2020 • New York
This Development, Manufacturing and Commercialization Agreement (the “Agreement”) is entered into as of August 14, 2006 (the “Effective Date”) between Corium International, Inc., a Delaware corporation having its principal place of business at 2686 Middlefield Road, Redwood City, CA 94063 and its manufacturing operations at 4558 50th Street, S.E., Grand Rapids, MI 49512, including its Affiliates (“Corium”), and Barr Laboratories, Inc., a Delaware corporation, having its principal place of business at 400 Chestnut Ridge Road, Woodcliff Lake, NJ 07677, including its Affiliates (including but not limited to Duramed Pharmaceuticals, Inc.) (“Barr”).
CONFIDENTIAL LICENSE, DEVELOPMENT, COLLABORATION, AND COMMERCIALIZATION AGREEMENT BY AND BETWEEN DANCE PHARMACEUTICALS, INC. AND AEROGEN LIMITED NOVEMBER 2010And Commercialization Agreement • May 21st, 2014 • Dance Biopharm, Inc. • Pharmaceutical preparations • New York
EX-10.5 3 a16-17137_1ex10d5.htm EX-10.5 RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTAnd Commercialization Agreement • May 5th, 2020 • Delaware
This Research, Development and Commercialization Agreement (“Agreement”) is entered into as of this 18th day of December, 2008, by and between:
Contract, and Commercialization Agreement • August 4th, 2017 • Pulmatrix, Inc. • Pharmaceutical preparations • Delaware
THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”.
COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTAnd Commercialization Agreement • November 14th, 2002 • Kosan Biosciences Inc • Services-commercial physical & biological research • Delaware
This Collaborative Research, Development and Commercialization Agreement (“Agreement”) is entered into as of this 19th day of September, 2002 (“Effective Date”), by and between:
AMENDMENT NO. 1 TO THE LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTAnd Commercialization Agreement • August 9th, 2016 • Theravance Biopharma, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 1 (“Amendment No. 1”) is entered into this 4th day of August, 2016 (“Amendment Effective Date”) and amends the Commercialization Agreement dated March 8, 2013, the current parties to which are Clinigen Group PLC, (“Clinigen”), and Theravance Biopharma Ireland Limited (referred to as “Theravance”). (the “Agreement”). Unless otherwise specifically stated herein, capitalized terms used herein and not defined shall have the same meaning set forth in the Agreement. References to “Sections” and “Exhibits” herein shall mean the corresponding sections and exhibits set forth in the Agreement.
FOURTH AMENDMENT TO DEVELOPMENT AND COMMERCIALIZATION AGREEMENTAnd Commercialization Agreement • May 25th, 2012 • ProUroCare Medical Inc. • Surgical & medical instruments & apparatus
THIS FOURTH AMENDMENT TO DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Fourth Amendment”) is made as of the 24th day of May, 2012, by and between Artann Laboratories, Inc. (“Artann”), a New Jersey corporation and ProUroCare Medical Inc. (“ProUroCare”), a Nevada corporation.
FIFTH AMENDMENT TO DEVELOPMENT AND COMMERCIALIZATION AGREEMENTAnd Commercialization Agreement • November 16th, 2012 • ProUroCare Medical Inc. • Surgical & medical instruments & apparatus
THIS FIFTH AMENDMENT TO DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Fifth Amendment”) is made as of the 27th day of October, 2012, by and between Artann Laboratories, Inc. (“Artann”), a New Jersey corporation and ProUroCare Medical Inc. (“ProUroCare”), a Nevada corporation.
AMENDMENT TO DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION AGREEMENTAnd Commercialization Agreement • May 5th, 2020 • New York
This is an Amendment to the Development, Manufacturing and Commercialization Agreement (the “Agreement”) dated April 27, 2015, between Perrigo UK Finco Limited Partnership, a United Kingdom limited partnership (“Perrigo UK”), and Sol-Gel Technologies Ltd., a limited liability company incorporated in Israel (“Sol-Gel”). Perrigo UK and Sol-Gel may hereafter be referred to collectively as the “Parties” and individually as a “Party.” The Effective Date of this Amendment is October 26, 2015 (the “Effective Date”).
AMENDMENT TO LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENT, and Commercialization Agreement • March 3rd, 2020 • Prothena Corp PLC • Pharmaceutical preparations
This AMENDMENT TO LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENT (the “Amendment”) is made effective June 6, 2018 (the “Amendment Effective Date”) hereby amends the and is to the LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENT (the “Agreement”) December 11, 2013 by and between NEOTOPE BIOSCIENCES LIMITED (as of January 5, 2015 PROTHENA BIOSCIENCES LIMITED, “Prothena Ireland”) with respect to all rights and obligations under this Agreement outside of the United States, and PROTHENA BIOSCIENCES INC. (“Prothena US”) with respect to all rights and obligations under this Agreement in the United States (Prothena US, together with Prothena Ireland, “Prothena”), on the one hand, and F. HOFFMANN-LA ROCHE LTD (“Roche Basel”) with respect to all rights and obligations under this Agreement outside of the United States, and HOFFMANN-LA ROCHE INC. (“Roche Nutley”) with respect to all rights and obligations under this Agreement in the United States (Roche Nutley, together with Roche Base
ContractAnd Commercialization Agreement • May 5th, 2020 • New York
EX-10.4 2 prta201310-kaex104rochelic.htm LICENSE AGREEMENT WITH ROCHE Exhibit 10.4 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENT BY AND BETWEEN NEOTOPE BIOSCIENCES LIMITED AND PROTHENA BIOSCIENCES INC, on the one hand, AND F. HOFFMANN-LA ROCHE LTD AND HOFFMANN-LA ROCHE INC., on the other hand December 11, 2013 TABLE OF CONTENTS
AMENDED AND RESTATED JOINT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BY AND AMONG GTC BIOTHERAPEUTICS, INC. AND LFB-BIOTECHNOLOGIES S.A.S.U. AND LFB/GTC LLC AND LFB BIOTECHNOLOGIES INC. June 30, 2008And Commercialization Agreement • August 7th, 2008 • GTC Biotherapeutics Inc • Biological products, (no disgnostic substances) • New York
This Amended and Restated Joint Development and Commercialization Agreement (this “Agreement”) is entered into as of June 30, 2008 (the “Restatement Date”), by and among GTC Biotherapeutics, Inc., a Massachusetts corporation, having offices at 175 Crossing Boulevard, Framingham, Massachusetts 01702, USA (“GTC”); LFB Biotechnologies S.A.S.U., a société par actions simplifiée unipersonnelle, having offices at 3, avenue des Tropiques, Les Ulis, 91958 Courtaboeuf, France (“LFB Biotech”); LFB/GTC LLC, a New York limited liability corporation, having offices at 175 Crossing Boulevard, Framingham, Massachusetts 01702, USA (“LFB/GTC LLC”) and LFB Biotechnologies Inc., a Delaware corporation having a registered office at 2711 Centerville Road, Suite 400, Wilmington, Delaware (“LFB-US”). GTC, LFB Biotech, LFB-US and LFB/GTC LLC are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BETWEEN AMPIO PHARMACEUTICALS, INC. AND DAEWOONG PHARMACEUTICALS CO., LTDAnd Commercialization Agreement • October 5th, 2011 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Agreement”) is made and entered into on August 23, 2011 (the “Effective Date”) by and between Ampio Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 5445 DTC Parkway, Suite 925, Greenwood Village, Colorado 80111 (“Ampio”), and Daewoong Pharmaceuticals Co., Ltd, having its principal place of business at 163-3 Samsungdong, Kangnam-gu, Seoul, Republic of Korea (“Daewoong”). Each of Ampio and Daewoong is sometimes referred to herein as a “Party” and collectively, as the “Parties.”
LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTAnd Commercialization Agreement • August 31st, 2007 • Anacor Pharmaceuticals Inc • Delaware
This License, Development, and Commercialization Agreement is entered into as of the Execution Date by and between Anacor Pharmaceuticals, Inc., a Delaware corporation having offices at 1060 East Meadow Circle, Palo Alto, CA 94303-4230 ("Anacor"), and Schering Corporation, a New Jersey corporation having offices at 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 ("Licensee").
PRODUCT RESEARCH, DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT by and between LES LABORATOIRES SERVIER and INSTITUT DE RECHERCHES SERVIER on the one hand AND INTERCEPT PHARMACEUTICALS, INC. on the other hand Effective Date: August 1st, 2011And Commercialization Agreement • September 27th, 2012 • Intercept Pharmaceuticals Inc • Pharmaceutical preparations
This Product Research, Development, License and Commercialization Agreement (this “Agreement”) is effective as of August 1st, 2011 (the “Effective Date”) and is entered into by and between INTERCEPT PHARMACEUTICALS, INC., a corporation organized and existing under the laws of Delaware, with registered office at 18 Desbrosses Street, New-York 10013 NY, USA (“INTERCEPT”) on the one hand and LES LABORATOIRES SERVIER, a corporation organized and existing under the laws of France, with registered office at 22 rue Garnier, 92578 Neuilly-sur-Seine cedex, France and INSTITUT DE RECHERCHES SERVIER, a corporation organized and existing under the laws of France, with registered office at 3 rue de la République, 92150 Suresnes, France (these two entities are jointly referred to as “SERVIER”) on the other hand.
AMENDMENT TO COLLABORATION, LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTAnd Commercialization Agreement • August 4th, 2017 • Aratana Therapeutics, Inc. • Pharmaceutical preparations
This Amendment to the Collaboration, License, Development and Commercialization Agreement (this “Amendment”), effective as of April 28, 2017, (the “Effective Date”) is entered into by and between Aratana Therapeutics, Inc., a Delaware corporation and having its office at 11400 Tomahawk Creek Parkway, Suite 340, Leawood, KS 66211 (“Aratana”) and Eli Lilly and Company, an Indiana corporation, operating on behalf of its Elanco Animal Health division and having its office at 2500 Innovation Way, Greenfield, Indiana 46140 and its Affiliates (“Elanco”).
SECOND AMENDMENT TO DEVELOPMENT AND COMMERCIALIZATION AGREEMENTAnd Commercialization Agreement • March 31st, 2010 • ProUroCare Medical Inc. • Surgical & medical instruments & apparatus
THIS SECOND AMENDMENT TO DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Second Amendment”) is made as of the 17th day of November, 2009, by and between Artann Laboratories, Inc. (“Artann”), a New Jersey corporation and ProUroCare Medical Inc. (“ProUroCare”), a Nevada corporation.
ContractAnd Commercialization Agreement • February 27th, 2013
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
UNDERSTANDING RELATED TO LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTAnd Commercialization Agreement • May 6th, 2020 • Prothena Corp PLC • Pharmaceutical preparations
This UNDERSTANDING RELATED TO LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENT (the “Understanding”) is made effective March 1, 2020 (the “Understanding Effective Date”) and hereby reflects the Parties’ understanding related to the LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENT (collectively, with all amendments thereto, being referred to as the “Agreement”) dated December 11, 2013 by and between Neotope Biosciences Limited (as of January 5, 2015 Prothena Biosciences limited, “Prothena Ireland”) with respect to all rights and obligations under this Agreement outside of the United States, and Prothena Biosciences Inc. (“Prothena US”) with respect to all rights and obligations under this Agreement in the United States (Prothena US, together with Prothena Ireland, “Prothena”), on the one hand, and F. Hoffmann-La Roche Ltd (“Roche Basel”) with respect to all rights and obligations under this Agreement outside of the United States, and Hoffmann-La Roche Inc. (“Roche Nutley”) wit
EXCLUSIVE LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTAnd Commercialization Agreement • November 14th, 2007 • Aradigm Corp • Electromedical & electrotherapeutic apparatus • New York
This Exclusive License, Development, and Commercialization Agreement (the “Agreement”) is entered into as of August 30, 2007 (the “Effective Date”) by and between Aradigm Corporation, a California corporation having its principal office at 3929 Point Eden Way, Hayward, California 94545 (“Aradigm”), and Lung Rx, Inc., a wholly-owned subsidiary of United Therapeutics Corporation, a Delaware corporation, having an address of 1110 Spring Street, Silver Spring, Maryland 20910 (“Lung Rx”). Aradigm and Lung Rx may be referred to individually as a “Party”, and collectively as the “Parties”.
FIRST AMENDMENT TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTAnd Commercialization Agreement • May 4th, 2017 • Agenus Inc • Biological products, (no disgnostic substances)
For clarity, no other milestones set forth in the Original Agreement shall apply with respect to the OX-40 Project or the GITR Project, and the milestones set forth in (F) through (H) above are payable only once across all Royalty-Bearing Products, based on aggregate sales of LAG-3 Products, TIM-3 Products, [********] Products, GITR Products, and OX-40 Products.
